Medicus Pharma Ltd. SEC filings MDCX
Medicus Pharma Ltd. has 343 filings in SEC EDGAR's recent list, going back to Oct 13, 2023. Its latest annual report, Form ARS, was filed on May 4, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 425 | Form 425 | Nov 4, 2026 | — |
| EFFECT | Filing | Mar 27, 2026 | — |
| EFFECT | Filing | Mar 27, 2026 | — |
| EFFECT | Filing | Mar 27, 2026 | — |
| 253G2 | Form 253g2 | Mar 6, 2026 | — |
| EFFECT | Filing | Feb 4, 2026 | — |
| CORRESP | Letter to the SEC | Jan 30, 2026 | — |
| UPLOAD | Letter from the SEC | Jan 15, 2026 | — |
| DRS | Filing | Jan 12, 2026 | — |
| EFFECT | Filing | Dec 31, 2025 | — |
| 253G2 | Form 253g2 | Dec 30, 2025 | — |
| CORRESP | Letter to the SEC | Dec 29, 2025 | — |
| DRS | Filing | Dec 10, 2025 | — |
| 253G2 | Form 253g2 | Dec 8, 2025 | — |
| EFFECT | Filing | Dec 4, 2025 | — |
| CORRESP | Letter to the SEC | Dec 2, 2025 | — |
| 253G2 | Form 253g2 | Dec 1, 2025 | — |
| 253G2 | Form 253g2 | Nov 17, 2025 | — |
| EFFECT | Filing | Nov 14, 2025 | — |
| EFFECT | Filing | Nov 14, 2025 | — |
| 253G2 | Form 253g2 | Oct 17, 2025 | — |
| DRS | Filing | Sep 19, 2025 | — |
| 253G2 | Form 253g2 | Sep 18, 2025 | — |
| 253G2 | Form 253g2 | Sep 15, 2025 | — |
| DRS | Filing | Sep 11, 2025 | — |
| 253G2 | Form 253g2 | Sep 2, 2025 | — |
| 253G2 | Form 253g2 | Aug 22, 2025 | — |
| 253G2 | Form 253g2 | Aug 12, 2025 | — |
| 253G2 | Form 253g2 | Jul 23, 2025 | — |
| 253G2 | Form 253g2 | Jul 14, 2025 | — |
| 253G2 | Form 253g2 | Jul 3, 2025 | — |
| UPLOAD | Letter from the SEC | Jul 1, 2025 | — |
| 253G2 | Form 253g2 | Jun 30, 2025 | — |
| 253G2 | Form 253g2 | Jun 24, 2025 | — |
| CORRESP | Letter to the SEC | Jun 23, 2025 | — |
| PRER14A | Form prer14a | Jun 23, 2025 | — |
| UPLOAD | Letter from the SEC | Jun 20, 2025 | — |
| 253G2 | Form 253g2 | Jun 20, 2025 | — |
| 253G2 | Form 253g2 | Jun 6, 2025 | — |
| 253G2 | Form 253g2 | Jun 3, 2025 | — |
| EFFECT | Filing | May 29, 2025 | — |
| EFFECT | Filing | May 29, 2025 | — |
| CORRESP | Letter to the SEC | May 28, 2025 | — |
| CORRESP | Letter to the SEC | May 28, 2025 | — |
| CORRESP | Letter to the SEC | May 27, 2025 | — |
| 253G2 | Form 253g2 | May 13, 2025 | — |
| UPLOAD | Letter from the SEC | May 5, 2025 | — |
| 253G2 | Form 253g2 | May 5, 2025 | — |
| DRS | Filing | May 1, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 30, 2025 | — |
| 253G2 | Form 253g2 | Apr 28, 2025 | — |
| DRS | Filing | Apr 25, 2025 | — |
| EFFECT | Filing | Apr 10, 2025 | — |
| QUALIF | Filing | Apr 10, 2025 | — |
| 1-A POS | Filing | Apr 4, 2025 | — |
| QUALIF | Filing | Apr 2, 2025 | — |
| 1-A POS | Filing | Mar 28, 2025 | — |
| 253G2 | Form 253g2 | Mar 28, 2025 | — |
| 253G1 | Form 253g1 | Mar 7, 2025 | — |
| QUALIF | Filing | Mar 6, 2025 | — |
| CORRESP | Letter to the SEC | Mar 6, 2025 | — |
| 1-A/A | Filing | Feb 28, 2025 | — |
| UPLOAD | Letter from the SEC | Feb 19, 2025 | — |
| 1-A | Filing | Feb 14, 2025 | — |
| CERT | Filing | Nov 14, 2024 | — |
| 8-A12B | Form 8-a12b | Nov 14, 2024 | — |
| EFFECT | Filing | Nov 13, 2024 | — |
| D/A | Filing | Jul 8, 2024 | — |
| D | Filing | Jun 18, 2024 | — |
| D | Filing | Oct 13, 2023 | — |
Showing 70 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MDCX (Nasdaq), MDCXW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Ontario, Canada
- Headquarters
- W. Conshohocken, PA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1997296
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.